Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
T A B L E O F C O N T E N T S<br />
HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1<br />
ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1<br />
PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2<br />
BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3<br />
OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5<br />
METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5<br />
RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7<br />
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9<br />
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10<br />
DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19<br />
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20<br />
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21<br />
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22<br />
Figure 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23<br />
Figure 7. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24<br />
Figure 8. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25<br />
Figure 9. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26<br />
Figure 10. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27<br />
AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29<br />
ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30<br />
REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30<br />
CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36<br />
DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109<br />
Analysis 1.1. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 1 Total Failure (P.<br />
falciparum) Day 63 PCR unadjusted. . . . . . . . . . . . . . . . . . . . . . . . . . 123<br />
Analysis 1.2. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 2 Total Failure (P.<br />
falciparum) Day 63 PCR adjusted. . . . . . . . . . . . . . . . . . . . . . . . . . . 124<br />
Analysis 1.3. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 3 Total Failure (P.<br />
falciparum) Day 42 PCR unadjusted. . . . . . . . . . . . . . . . . . . . . . . . . . 125<br />
Analysis 1.4. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 4 Total Failure (P.<br />
falciparum) Day 42 PCR adjusted. . . . . . . . . . . . . . . . . . . . . . . . . . . 125<br />
Analysis 1.5. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 5 Total Failure (P.<br />
falciparum) Day 28 PCR unadjusted. . . . . . . . . . . . . . . . . . . . . . . . . . 126<br />
Analysis 1.6. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 6 Total Failure (P.<br />
falciparum) Day 28 PCR adjusted. . . . . . . . . . . . . . . . . . . . . . . . . . . 126<br />
Analysis 1.7. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 7 P. vivax<br />
parasitaemia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127<br />
Analysis 1.8. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 8 Gametocyte<br />
development (in those negative at baseline). . . . . . . . . . . . . . . . . . . . . . . . 129<br />
Analysis 1.9. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 9 Gametocytaemia<br />
carriage. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130<br />
Analysis 1.10. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 10 Serious adverse<br />
events (including deaths). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131<br />
Analysis 1.11. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 11 Early<br />
vomiting. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132<br />
Analysis 1.12. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 12 Sensitivity<br />
analysis: Total Failure Day 63 PCR unadjusted. . . . . . . . . . . . . . . . . . . . . . . 133<br />
Analysis 1.13. Comparison 1 Dihydroartemisinin-piperaquine vs Artesunate plus mefloquine, Outcome 13 Sensitivity<br />
analysis: Total Failure Day 63 PCR adjusted. . . . . . . . . . . . . . . . . . . . . . . . 134<br />
Analysis 2.1. Comparison 2 Dihydroartemisinin-piperaquine vs Artemether-lumefantrine, Outcome 1 Total Failure (P.<br />
falciparum) Day 42 PCR unadjusted. . . . . . . . . . . . . . . . . . . . . . . . . . 136<br />
<strong>Artemisinin</strong>-<strong>based</strong> <strong>combination</strong> <strong>therapy</strong> <strong>for</strong> treating uncomplicated malaria (Review)<br />
Copyright © 2009 <strong>The</strong> <strong>Cochrane</strong> Collaboration. Published by John Wiley & Sons, Ltd.<br />
i